|
1
|
Saginala K and Barsouk A, Aluru JS, Rawla
P, Padala SA and Barsouk A: Epidemiology of bladder cancer. Med Sci
(Basel). 8(15)2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Powles T, Rosenberg JE, Sonpavde GP,
Loriot Y, Durán I, Lee JL, Matsubara N, Vulsteke C, Castellano D,
Wu C, et al: Enfortumab vedotin in previously treated advanced
urothelial carcinoma. N Engl J Med. 384:1125–1135. 2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Fardet L, Galicier L, Lambotte O, Marzac
C, Aumont C, Chahwan D, Coppo P and Hejblum G: Development and
validation of the HScore, a score for the diagnosis of reactive
hemophagocytic syndrome. Arthritis Rheumatol. 66:2613–2620.
2014.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Marchand L, Disse E, Dalle S, Reffet S,
Vouillarmet J, Fabien N, Thivolet C and Cugnet-Anceau C: The
multifaceted nature of diabetes mellitus induced by checkpoint
inhibitors. Acta Diabetol. 56:1239–1245. 2019.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Kotwal A, Haddox C, Block M and Kudva YC:
Immune checkpoint inhibitors: An emerging cause of
insulin-dependent diabetes. BMJ Open Diabetes Res Care.
7(e000591)2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Mourad D, Azar NS, Eid AA and Azar ST:
Immune checkpoint inhibitor-induced diabetes mellitus: Potential
role of T cells in the underlying mechanism. Int J Mol Sci.
22(2093)2021.PubMed/NCBI View Article : Google Scholar
|
|
7
|
U.S. Food and Drug Administration: Full
prescribing information: KEYTRUDA. U.S. Food and Drug
Administration, Silver Spring, MD, 2014.
|
|
8
|
Yu EY, Petrylak DP, O'Donnell PH, Lee JL,
van der Heijden MS, Loriot Y, Stein MN, Necchi A, Kojima T,
Harrison MR, et al: Enfortumab vedotin after PD-1 or PD-L1
inhibitors in cisplatin-ineligible patients with advanced
urothelial carcinoma (EV-201): A multicentre, single-arm, phase 2
trial. Lancet Oncol. 22:872–882. 2021.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Chang E, Weinstock C, Zhang L, Charlab R,
Dorff SE, Gong Y, Hsu V, Li F, Ricks TK, Song P, et al: FDA
approval summary: Enfortumab vedotin for locally advanced or
metastatic urothelial carcinoma. Clin Cancer Res. 27:922–927.
2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Kwok B, Bhatt A, Wise WJ and Gibson CD:
Refractory diabetic ketoacidosis related to Enfortumab vedotin
monotherapy for metastatic urothelial carcinoma. Am J Respir Crit
Care Med. 201(A1736)2020.
|
|
11
|
Iftikhar H and Khoury C: Enfortumab
vedotin-induced diabetic ketoacidosis and AKI: A case report.
Kidney Int Rep. 1 (2 Suppl):S8–S9. 2022.
|
|
12
|
Patel J: Enfortumab vedotin induced
hyperglycemia and diabetic ketoacidosis. Am J Respir Crit Care Med.
207(A5298)2023.
|
|
13
|
Elahi A, Duron J and Porter T: Intractable
diabetic ketoacidosis with Enfortumab vedotin. Diabetes. 72 (Suppl
1):1851–PUB. 2023.
|
|
14
|
Sato T, Suzuki H, Asashima Y and Sone H:
Enfortumab Vedotin-induced hyperglycemia and ileal conduit
reconstruction-induced metabolic acidosis. JCEM Case Rep.
1(luad092)2023.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Bonora E and Tuomilehto J: The pros and
cons of diagnosing diabetes with A1C. Diabetes Care. 34 (Suppl
2):S184–S190. 2011.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Treister-Goltzman Y, Liberty IF and Peleg
R: Ethnicity affects A1C levels in patients with diagnosed type 2
diabetes in Southern Israel. Diabetes Spectr. 37:86–94.
2024.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Zhu B, Bu L, Zhang M, Gusdon AM, Zheng L,
Rampersad S, Li J and Qu S: HbA1c as a screening tool for ketosis
in patients with type 2 diabetes mellitus. Sci Rep.
23(39687)2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Chiang JM, Lai AR, Anderson M and
Rushakoff RJ: Severe insulin resistance with diabetic ketoacidosis
after Brentuximab treatment. AACE Clin Case Rep. 6:e98–e100.
2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Thakkar K, Khurana S, Sun Y and Hembree
TN: Diabetic ketoacidosis and profound insulin resistance from
Brentuximab vedotin. Cureus. 15(e35804)2023.PubMed/NCBI View Article : Google Scholar
|
|
20
|
McHugh D, Eisenberger M, Heath EI, Bruce
J, Danila DC, Rathkopf DE, Feldman J, Slovin SF, Anand B, Chu R, et
al: A phase I study of the antibody drug conjugate ASG-5ME, an
SLC44A4-targeting antibody carrying auristatin E, in metastatic
castration-resistant prostate cancer. Invest New Drugs.
37:1052–1060. 2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Danila DC, Szmulewitz RZ, Vaishampayan U,
Higano CS, Baron AD, Gilbert HN, Brunstein F, Milojic-Blair M, Wang
B, Kabbarah O, et al: Phase I study of DSTP3086S, an antibody-drug
conjugate targeting six-transmembrane epithelial antigen of
prostate 1, in metastatic castration-resistant prostate cancer. J
Clin Oncol. 37:3518–3527. 2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Best RL, LaPointe NE, Azarenko O, Miller
H, Genualdi C, Chih S, Shen BQ, Jordan MA, Wilson L, Feinstein SC
and Stagg NJ: Microtubule and tubulin binding and regulation of
microtubule dynamics by the antibody drug conjugate (ADC) payload,
monomethyl auristatin E (MMAE): Mechanistic insights into MMAE ADC
peripheral neuropathy. Toxicol Appl Pharmacol.
15(115534)2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Masters JC, Nickens DJ, Xuan D, Shazer RL
and Amantea M: Clinical toxicity of antibody drug conjugates: A
meta-analysis of payloads. Invest New Drugs. 36:121–135.
2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Li J, Shen G, Liu Z, Liu Y, Wang M, Zhao
F, Ren D, Xie Q, Li Z, Liu Z, et al: Treatment-related adverse
events of antibody-drug conjugates in clinical trials: A systematic
review and meta-analysis. Cancer Innov. 15:346–375. 2023.PubMed/NCBI View
Article : Google Scholar
|
|
25
|
U.S. Food and Drug Administration: Full
prescribing information: PADCEV. U.S. Food and Drug Administration,
Silver Spring, MD, 2019.
|
|
26
|
La Rosée P, Horne A, Hines M, von Bahr
Greenwood T, Machowicz R, Berliner N, Birndt S, Gil-Herrera J,
Girschikofsky M, Jordan MB, et al: Recommendations for the
management of hemophagocytic lymphohistiocytosis in adults. Blood.
133:2465–2477. 2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Saugel B, Jakobus J, Huber W, Hoffmann D,
Holzapfel K, Protzer U, Schmid RM and Umgelter A: Herpes simplex
virus in bronchoalveolar lavage fluid of medical intensive care
unit patients: Association with lung injury and outcome. J Crit
Care. 32:138–144. 2016.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Machaczka M, Vaktnäs J, Klimkowska M and
Hägglund H: Malignancy-associated hemophagocytic
lymphohistiocytosis in adults: A retrospective population-based
analysis from a single center. Leuk Lymphoma. 52:613–619.
2011.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Ramos-Casals M, Brito-Zerón P,
López-Guillermo A, Khamashta MA and Bosch X: Adult haemophagocytic
syndrome. Lancet. 26:1503–1516. 2014.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Malissen N, Lacotte J, Du-Thanh A,
Gaudy-Marqueste C, Guillot B and Grob JJ: Macrophage activation
syndrome: A new complication of checkpoint inhibitors. Eur J
Cancer. 77:88–89. 2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Wang C, Sun W, Li Z, Wu T and Fang W:
Clinical characteristics, treatment, and management of
pembrolizumab induced hemophagocytic lymphohistiocytosis. Invest
New Drugs. 41:834–841. 2023.PubMed/NCBI View Article : Google Scholar
|
